You are here

FDA Approves Desogestrel and Ethinyl Estradiol Tablets

CORONA, Calif., Aug. 1 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE:WPI) , a leading specialty pharmaceutical company, announced today that it has received final approval from the United States (U.S.) Food and Drug Administration (FDA) on its Abbreviated New Drug Application for desogestrel and ethinyl estradiol tablets USP, 0.15mg / 0.03mg, a generic version of Ortho-McNeil's Ortho-Cept(R) and Organon's Desogen(R) products which are indicated for the prevention of pregnancy.

The Company intends to initiate shipments of the product immediately. For the 12-months ending March 2005, desogestrel and ethinyl estradiol tablets USP, 0.15mg / 0.03mg market had total U.S. sales of approximately $180 million, according to IMS Health data.

Source: Watson Pharmaceuticals, Inc.

Recent Headlines

A new 'road map' might make it easier
Rationing, canceled treatments, and fearful patients
Your heart will thank you
Seems like the 2013 Guidelines are having an impact
Biomarker blood tests pick up subtle clues
Meeting 'zombie cells' along the way
Hovering flights lower packages by cable and winch
Ziextenzo helps lower the incidence of febrile neutropenia